Lymphangioleiomyomatosis (LAM) is a rare lung disease characterized by the uncontrolled growth of smooth like muscle cells (LAM cells) in the lungs that can spread to other body parts via the lymphatic system Current treatment for LAM is oral Rapamycin, which is limited by its low bioavailability (~15%) and side effects [1, 2]. It???s been shown that particles of approximately <1000nm with a negative surface charge are able to enter the lymphatic system The current study aimed to determine the optimum size of Rapamycin solid lipid nanoparticles (SLN) that will facilitate drug entry into the lymphatic system through the inhaled route in order to increase lung bioavailability, reduce systemic side effects and potentially have increased efficacy. The current study showed that Rapamycin-SLN with negative surface charge and size of approximately 200nm is able to cross the lung epithelium faster than larger particles.
Published Date: 2021-10-22;